Abstract Details

Title CAR T-cell Therapy in Glioblastoma: A Systematic Review and Meta-analysis of Clinical Trials

Topic Neuro-oncology

Presentation(s) P11 - Poster Session 11 (11:45 AM-12:45 PM)

Poster/Presentation
Number 6-011

Objective To assess pooled survival, response and toxicity outcomes of CAR T-cell therapy in glioblastoma.

Background Glioblastoma is the most aggressive brain tumor. CAR T-cell therapy has emerged as an innovative approach targeting tumor-associated antigens such as EGFRvIII, IL13Rα2, HER2, and B7-H3, though clinical efficacy remains uncertain.

Design/Methods A systematic search of PubMed, Embase, and Cochrane identified clinical trials evaluating CAR T-cell therapy in GBM. Pooled median overall survival (OS) and progression-free survival (PFS) were estimated by the quantile estimation method. Analyses also included overall response rate (ORR), disease control rate (DCR), complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), Grade 3–4 adverse events (AE), and death. Random-effects models estimated pooled proportions with 95% confidence intervals, and heterogeneity was assessed using I² and p-values from Cochran’s Q test. Analyses were performed in R (v4.5.1).

Results

Fourteen trials comprising 190 patients receiving CAR T-cells therapy were included. The pooled median OS was 9.54 months (95% CI, 7.41-12.29), and median PFS was 2.25 months (95% CI, 1.29-3.93). The pooled ORR was 16% (95% CI, 8–31%; I² = 53.4%, p = 0.0182), while DCR reached 53% (95% CI, 43–63%; I² = 15.6%, p = 0.2956). Response stratification showed CR = 17% (95% CI, 2–73%; I² = 80.3%, p = 0.0063), PR = 14% (95% CI, 5–32%; I² = 62.0%, p = 0.0219), SD = 44% (95% CI, 36–52%; I² = 0.0%, p = 0.4493), and PD = 54% (95% CI, 41–66%; I² = 40.2%, p = 0.0731). Grade 3–4 AE occurred in 43% (95% CI, 29–58%; I² = 51.6%, p = 0.0237), and mortality was 78% (95% CI, 64–88%; I² = 47.4%, p = 0.0293).

Conclusions CAR T-cell therapy demonstrated modest tumor control, limited objective responses, and reduced survival. Despite DCR above 50%, high mortality and toxicity highlight the need for optimized CAR therapy.

Authors/Disclosures
Barbara Antonia D. Talah, Medical Student PRESENTER	Miss Talah has nothing to disclose.
Pedro Bartkevitch Rodrigues, MD	Dr. Bartkevitch Rodrigues has nothing to disclose.
Francisco de Moraes	Francisco de Moraes has nothing to disclose.
Lucas D. Vital, Medical student	Mr. Vital has nothing to disclose.
Mayara S. Marques, MD	Miss Marques has nothing to disclose.
Kristel Back Merida, MD	Dr. Back Merida has nothing to disclose.

��ɫ��

��ɫ��